Explained: Why West Asia Conflict Is Impacting India’s Medicine Supply Chain

India’s pharmaceutical sector is facing fresh cost pressures as the ongoing tensions in West Asia disrupt global logistics and input supplies. Industry leaders warn that rising freight, insurance, and raw material costs are beginning to strain supply chains, even as efforts are underway to prevent any disruption in medicine availability.

What is driving the rise in pharma costs?

According to Sudarshan Jain, General Secretary of the Indian Pharmaceutical Alliance, multiple cost components have seen a noticeable increase due to the crisis. Freight charges have gone up as shipping routes face uncertainty, insurance premiums have risen amid geopolitical risks, and the cost of solvents—key inputs in drug manufacturing—has also climbed.

“Yes, there has been a definite increase in the freight cost. There is an insurance cost which has gone up and there is a cost increase in the solvent. We are working very closely with the government and the primary task at the moment is to ensure that the products are available because we owe a lot to the world that we supply to more than 200 countries and the patients around the world depend on us,” Jain said.

Will medicine supplies be affected?

Despite these pressures, the industry insists that maintaining uninterrupted supply remains the top priority. India plays a crucial role in global healthcare, supplying medicines to over 200 countries, and any disruption could have widespread consequences.

Jain underscored that both the government and industry are actively coordinating to avoid shortages and delays.

“The Department of Pharmaceuticals, Commerce Ministry, and the industry are working together to ensure that inputs are available and products are supplied on time to patients globally,” he noted.

Why is India’s pharma sector strategically important?

India’s pharmaceutical industry is not just a domestic necessity but a global lifeline. The country has a strong manufacturing base, including the highest number of USFDA-approved plants worldwide, reinforcing its reputation as a reliable supplier of affordable medicines.

The sector contributes around USD 30 billion each to exports and the domestic market, making it a key pillar of the economy.

What is the long-term vision for the sector?

Looking ahead, the industry is aiming for significant expansion, with a long-term goal of contributing USD 450 billion by 2047. Innovation—especially affordable innovation at scale—is expected to drive this growth.

“The sector can be a very great contributor to the country. What will play an important role going forward is innovation, especially affordable innovation at scale,” Jain said.

Industry leaders have also aligned on a roadmap to develop more than 100 new products by 2047, alongside efforts to strengthen regulatory systems and position India as a global benchmark in pharmaceuticals.

(With inputs from ANI)